卒中预防试验参与者的残疾与复发性卒中
该研究为PRoFESS与IRIS两项卒中二级预防临床试验数据集的事后队列分析,共纳入PRoFESS 20 183例(平均年龄66.1岁,男性64.1%)和IRIS 3 265例(平均年龄62.7岁,男性65.9%)。暴露为基线mRS 0 vs 1-2 vs ≥3。PRoFESS中复发性卒中率分别为7.2%、8.7%、10.6%(χ²₂=27.1;P<.001);IRIS中分别为6.4%、9.0%、11.7%(χ²₂=11.1;P<.001)。与mRS 0相比,mRS≥3者复发性卒中HR在PRoFESS为1.63(95%CI 1.38-1.92;P<.001),IRIS为1.91(95%CI 1.28-2.86;P=.002)。作者认为,在卒中预防试验中纳入更多基线残疾较重患者可能提高统计效能与普遍性。
要点
- PRoFESS中复发性卒中率:mRS 0为7.2%,mRS 1-2为8.7%,mRS≥3为10.6%(χ²₂=27.1;P<.001)。
- IRIS中复发性卒中率:mRS 0为6.4%,mRS 1-2为9.0%,mRS≥3为11.7%(χ²₂=11.1;P<.001)。
- 与mRS 0相比,mRS≥3者复发性卒中风险:PRoFESS HR 1.63(95%CI 1.38-1.92;P<.001),IRIS HR 1.91(95%CI 1.28-2.86;P=.002)。
- MACE率在PRoFESS为mRS 0 10.1%、mRS 1-2 12.2%、mRS≥3 17.2%(χ²₂=103.4;P<.001),IRIS为10.9%、13.3%、15.3%(χ²₂=5.8;P=.06)。
- 与mRS 0相比,mRS≥3者MACE风险:PRoFESS HR 1.90(95%CI 1.66-2.18;P<.001),IRIS HR 1.45(95%CI 1.03-2.03;P=.03)。
适用人群与场景
- PRoFESS参与者20 183例,平均(SD)年龄66.1(8.5)岁,男性12 931例(64.1%),入组时间2003年至2008年。
- IRIS参与者3 265例,平均(SD)年龄62.7(10.6)岁,男性2 151例(65.9%),入组时间2005年至2015年。
诊断标准与关键阈值
- 暴露为研究基线时卒中后功能状态,采用改良Rankin量表(mRS;范围0-5分,评分越高残疾越重)分为0分 vs 1-2分 vs ≥3分。
研究设计与关键结果
- 研究类型为PRoFESS与IRIS二次预防临床试验数据集的事后队列分析,数据分析时间为2023年9月23日至2024年5月16日。
- 随访中位(IQR)时间:PRoFESS为2.4(1.9-3.0)年,IRIS为4.7(3.2-5.0)年。
- PRoFESS复发性卒中率:mRS 0为7.2%,mRS 1-2为8.7%,mRS≥3为10.6%(χ²₂=27.1;P<.001)。
- IRIS复发性卒中率:mRS 0为6.4%,mRS 1-2为9.0%,mRS≥3为11.7%(χ²₂=11.1;P<.001)。
- PRoFESS的MACE率:mRS 0为10.1%,mRS 1-2为12.2%,mRS≥3为17.2%(χ²₂=103.4;P<.001)。
- IRIS的MACE率:mRS 0为10.9%,mRS 1-2为13.3%,mRS≥3为15.3%(χ²₂=5.8;P=.06)。
- 与mRS 0相比,mRS≥3者复发性卒中风险:PRoFESS HR 1.63(95%CI 1.38-1.92;P<.001),IRIS HR 1.91(95%CI 1.28-2.86;P=.002)。
- 与mRS 0相比,mRS≥3者MACE风险:PRoFESS HR 1.90(95%CI 1.66-2.18;P<.001),IRIS HR 1.45(95%CI 1.03-2.03;P=.03)。
证据类型、等级与局限
- 证据类型:PRoFESS与IRIS临床试验数据集的post hoc队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在卒中预防试验中纳入更多基线残疾较重患者可能提高统计效能与普遍性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Stroke secondary prevention trials have disproportionately enrolled participants with mild or no disability. The impact of this bias remains unclear.
OBJECTIVE: To investigate the association between poststroke disability and the rate of recurrent stroke during long-term follow up.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a post hoc analysis of the Prevention Regimen For Effectively Avoiding Second Strokes (PRoFESS) and Insulin Resistance Intervention After Stroke (IRIS) secondary prevention clinical trial datasets. PRoFESS enrolled patients from 2003 to 2008, and IRIS enrolled patients from 2005 to 2015. Data were analyzed from September 23, 2023, to May 16, 2024.
EXPOSURE: The exposure was poststroke functional status at study baseline, defined as modified Rankin Scale (mRS; range, 0-5; higher score indicates more disability) score of 0 vs 1 to 2 vs 3 or greater.
MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent stroke. The secondary outcome was major cardiovascular events (MACE), defined as recurrent stroke, myocardial infarction, new or worsening heart failure, or vascular death.
RESULTS: A total of 20 183 PRoFESS participants (mean [SD] age, 66.1 [8.5] years; 12 931 [64.1%] male) and 3265 IRIS participants (mean [SD] age, 62.7 [10.6] years; 2151 [65.9%] male) were included. The median (IQR) follow-up was 2.4 (1.9-3.0) years in PRoFESS and 4.7 (3.2-5.0) years in IRIS. In PRoFESS, the recurrent stroke rate was 7.2%, among patients with an mRS of 0, 8.7% among patients with an mRS of 1 or 2, and 10.6% among patients with an mRS of 3 or greater (χ22 = 27.1; P < .001); in IRIS the recurrent stroke rate was 6.4% among patients with an mRS of 0, 9.0% among patients with an mRS of 1 or 2, and 11.7% among patients with an mRS of 3 or greater (χ22 = 11.1; P < .001). The MACE rate was 10.1% among patients with an mRS of 0, 12.2% among patients with an mRS of 1 or 2, and 17.2% among patients with an mRS of 3 or greater (χ22 = 103.4; P < .001) in PRoFESS and 10.9% among patients with an mRS of 0, 13.3% among patients with an mRS of 1 or 2, and 15.3% among patients with an mRS of 3 or greater (χ22 = 5.8; P = .06) in IRIS. Compared with patients with an mRS of 0, patients with an mRS of 3 or greater had increased hazard for recurrent stroke in PRoFESS (hazard ratio [HR], 1.63; 95% CI, 1.38-1.92; P < .001) and in IRIS (HR, 1.91; 95% CI, 1.28-2.86; P = .002). There was also increased hazard for MACE in PRoFESS (HR, 1.90; 95% CI, 1.66-2.18; P < .001) and in IRIS (HR, 1.45; 95% CI, 1.03-2.03; P = .03).
CONCLUSIONS AND RELEVANCE: This cohort study found that higher baseline poststroke disability was associated with increased rates of recurrent stroke and MACE. Including more patients with greater baseline disability in stroke prevention trials may improve the statistical power and generalizability of these studies.
参考来源
- de Havenon A, Viscoli C, Kleindorfer D, et al. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Netw Open. 2024. PMID: 39028666. doi:10.1001/jamanetworkopen.2024.23677
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。